Inselspital, Bern University Hospital | Cancer Care in Bern

Inselspital has historical roots in Bern dating to the fourteenth century and has developed into a university hospital serving clinical care, teaching and research. Its connection with the University of Bern places cancer treatment within an academic setting where specialist practice and research are linked.

The cancer service is best understood as a network of hospital-based programmes rather than a single clinic treating every diagnosis in the same way. Medical oncology, surgical specialties, radiation oncology, haematology, pathology and imaging contribute according to the patient's needs. It operates within a large, multispecialty hospital; no current cancer-specific patient-volume or bed figure is provided here.

The centre's profile highlights neuro-oncology and complex neurosurgery, alongside stem cell transplantation for selected blood disorders and cancers. Multidisciplinary tumour boards across all major organ programmes bring relevant specialists together to review findings and recommend management. A board recommendation still requires discussion with the patient about expected benefits, risks and alternatives.

Brain tumour care is a particular focus, combining neuro-oncology with neurosurgical assessment and other treatments where appropriate. Management depends on tumour location, pathological and molecular classification, neurological function and previous therapy. Complex neurosurgery may be relevant to selected cases, but operability must be assessed individually rather than inferred from the centre's capabilities.

Lung and breast cancer programmes involve decisions about surgery, radiotherapy and systemic treatment according to stage and tumour biology. Biomarker findings can influence treatment selection, especially when targeted drugs or immunotherapy are being considered. Specialist review may also clarify whether further diagnostic testing is needed.

Blood cancer care includes conditions for which stem cell transplantation may be considered. Sarcoma is another listed specialty, where expert pathology review and coordinated surgical, radiation and medical oncology input can be important. Patients should confirm experience with their exact subtype, particularly for rare diagnoses.

Surgery forms part of treatment for many solid tumours, including selected brain, lung, breast and soft-tissue or bone tumours. The proposed operation depends on anatomy, disease extent and the balance between cancer control and preservation of function. Complex procedures may require rehabilitation and a longer local recovery period.

Radiation therapy may be used as a principal treatment, alongside surgery or medicines, or to relieve symptoms. Patients should ask which technique is proposed and how many visits it involves. The availability of radiotherapy does not establish that a particular specialist technology is offered or appropriate for an individual case.

Systemic treatment options include immunotherapy and targeted therapy, with chemotherapy also relevant to many oncology and haematology pathways. Precision oncology uses features of the tumour, including molecular findings when informative, to guide decisions. Testing does not guarantee a matching drug, a clinical benefit or reimbursement for the recommended medicine.

Stem cell transplantation is an option for selected blood cancers following detailed assessment. It can involve substantial infection risk, monitoring and recovery requirements. Across treatments, patients should discuss symptom control, supportive care and rehabilitation, as well as the distinction between treatment intended to cure, control disease or improve comfort.

The supplied profile describes around 150 active oncology clinical trials. This figure is indicative: trial portfolios change, and an active study may be in follow-up rather than recruiting. It should not be interpreted as the number of trials available to a particular patient. Current study status and site participation need confirmation with the relevant clinical team.

An international patient can ask for trial consideration during specialist assessment, supported by pathology, staging information, molecular results and a complete treatment history. Eligibility may depend on specific biomarkers, previous medicines, organ function, performance status and other conditions. Screening can require additional tests, and an initial discussion does not guarantee enrolment.

Before travelling, clarify visit frequency, mandatory procedures, language requirements for informed consent and arrangements for complications. Ask which research-related costs are covered and which routine-care or travel expenses remain payable. Participation is voluntary, and experimental treatment may not be better than standard care.

Begin by asking the hospital how to submit a referral to the appropriate cancer programme and whether an initial records-based assessment is possible. Provide a concise clinical summary and identify the decision you need help with, such as diagnosis confirmation, surgery assessment or further treatment options. Obtain confirmation of the proposed appointment and financial arrangements before booking non-refundable travel.

Plan the return-home phase alongside the hospital visit. Clarify who will prescribe ongoing medicines, review scans and manage urgent symptoms after departure. Your local oncologist may need to coordinate with the Bern team, particularly after surgery, transplantation or trial treatment. Ask whether your condition allows travel and whether a companion is advisable; the necessary stay may extend beyond the first appointment.

Contact details below come from the hospital's own published international patient information.

Location: Bern, Switzerland

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +41 31 632 21 11

Website: https://www.insel.ch

Languages supported: German, French, English

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.